Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Ascendis Pharma A/S (ASND) Stock Price
News stories about Ascendis Pharma A/S (NASDAQ:ASND) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Ascendis Pharma A/S earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.6377875651133 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Versartis Stock Crashes After Drug Fails; Rival Ascendis Pharma Soars (investors.com)
- Why L Brands, Ascendis Pharma, and Phillips 66 Partners Jumped Today (nwitimes.com)
- This Biotech Is Ascending To Record Highs After Rival's Failure (finance.yahoo.com)
- Ascendis Pharma A/S (ASND) Receives “Buy” Rating from Wells Fargo & Company (americanbankingnews.com)
- Is Ascendis Pharma A/S (ASND) Thriving Or Barely Surviving In The Healthcare Sector? (finance.yahoo.com)
Several research firms have recently commented on ASND. BidaskClub downgraded shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a report on Wednesday, August 9th. Wedbush reaffirmed an “outperform” rating and issued a $10.71 price objective (down from $65.00) on shares of Ascendis Pharma A/S in a report on Friday. Zacks Investment Research downgraded shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a report on Wednesday, August 23rd. ValuEngine raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Saturday, May 27th. Finally, Credit Suisse Group reaffirmed an “outperform” rating and issued a $50.00 price objective (up from $30.00) on shares of Ascendis Pharma A/S in a report on Friday. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $33.29.
Shares of Ascendis Pharma A/S (NASDAQ:ASND) opened at 34.24 on Friday. Ascendis Pharma A/S has a one year low of $17.15 and a one year high of $42.00.
Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Friday, August 18th. The biotechnology company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.24). The business had revenue of $0.44 million during the quarter, compared to analyst estimates of $0.78 million. Ascendis Pharma A/S had a negative net margin of 2,977.70% and a negative return on equity of 67.76%. The business’s revenue was down 61.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.53) earnings per share. Equities analysts predict that Ascendis Pharma A/S will post ($0.17) EPS for the current year.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.